This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche (RHHBY) to Acquire Jecure and Enter the NASH Space
by Zacks Equity Research
Roche (RHHBY) is all set to acquire biotech Jecure Therapeutics, which focuses on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis.
Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial
by Zacks Equity Research
Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with Yervoy fails to meet the goal in a late-stage study for extensive-stage SCLC.
Roche, AbbVie Get FDA Approval for Venclexta Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets accelerated approval for Venclexta for the treatment of patients suffering from newly-diagnosed AML who are aged 75 years or older.
Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC
by Zacks Equity Research
Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with low-dose Yervoy gets positive opinion from CHMP for the treatment of intermediate- and poor-risk advanced RCC.
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
by Zacks Equity Research
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
Roche's Tecentriq Gets Priority Review for Breast Cancer
by Zacks Equity Research
Roche's efforts to expand the label of its immuno-oncology drug Tecentriq advances as the FDA accepts its sBLA and grants priority review for the treatment of breast cancer.
Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) Q3 loss betters estimates. Also, revenues match the consensus mark.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.
Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Mylan's (MYL) Q3 revenues lag estimates due to persistent challenges in the North America segment.
Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.
ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.
Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenue beat expectations in the third-quarter propelled by strong sales of Cabometyx.
TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up
by Zacks Equity Research
TESARO (TSRO) beats estimates for earnings in the third quarter but misses the same on revenues. Zejula sales maintain momentum.
AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings top estimates while revenues fall short. Revenues increase year over year on strong sales growth of Humira, Imbruvica and Mavyret.
Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.
The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead
by Kinjel Shah
Pipeline success, cost cutting, share buybacks, product launches, increased M&A and collaboration activities are the factors that drives the large-cap pharma industry.
Exelixis (EXEL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) third-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
Can the Strong Economy Save the Stock Market?
by John Blank
The U.S. economy is the MOST important fundamental.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised)
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC
by Zacks Equity Research
The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines
by Zacks Equity Research
Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
Earnings Keep Pouring In: Global Week Ahead
by John Blank
So far, almost 90% of the firms have beaten analysts' earnings expectations. About 70% have beaten revenue expectations. This week, 156 S&P 500 firms release earnings.
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.